Key facts
- This page summarizes Michael Sinclair's Form 4 filing for OPIANT PHARMACEUTICALS, INC..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jun 2022, 16:39.
Michael Sinclair - 06 Jun 2022 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 06 Jun 2022
- Net transaction value
- -$109,771
- SEC form
- 4
- Accepted by SEC
- 08 Jun 2022, 16:39:12 UTC
- Prior SEC filing
- 06 Jun 2022
- Next SEC filing
- 13 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Sinclair
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Sinclair filed Form 4 for OPIANT PHARMACEUTICALS, INC. on 08 Jun 2022.
Change
- Previous filing in this sequence was filed on 06 Jun 2022.
- Current net transaction value: -$109,771.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OPNT
transaction
Common Stock
Sale
- Transaction value
- $99,483
- Shares
- -7,688
- Change %
- -16%
- Price
- $12.94
- Shares after
- 41,532
- Date
- 06 Jun 2022
- Ownership
- Direct
OPNT
transaction
Common Stock
Sale
- Transaction value
- $10,288
- Shares
- -800
- Change %
- -1.9%
- Price
- $12.86
- Shares after
- 40,732
- Date
- 07 Jun 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.